Neoadjuvant Chemotherapy Improves Survival in Diffuse Type Gastric and Gastroesophageal Junction Carcinoma

Multimodal therapy, specifically neoadjuvant chemotherapy, was associated with increased survival in patients with diffuse type gastric and gastroesophageal junction carcinoma, including signet ring cell carcinoma. All-cause mortality within 90 days postoperatively was lower after neoadjuvant chemotherapy compared to primary surgery. Additionally, mortality remained lower in the neoadjuvant chemotherapy group even after 90 days post-surgery. These findings suggest the potential benefit of neoadjuvant chemotherapy in improving outcomes for patients with these types of cancers.